Susan Jackson

Susan Jackson is a Clinical Research Fellow and DPhil student at the University of Oxford, affiliated with the Tuberculosis vaccine programme at the Jenner Institute and the Oxford Vaccine Group. She works under the supervision of Professor Helen McShane and has contributed to the COVID-19 vaccine trial team led by Professor Andrew Pollard.

Her educational background includes a BMedSci(hons) and BMBS(hons) from Nottingham University. She is currently enrolled in the Respiratory Medicine training programme within the Thames Valley deanery, with plans to resume clinical training after completing her DPhil.

• Research Focus: Tuberculosis vaccinology and COVID-19 vaccine development, specializing in immunogenicity, safety, and efficacy of viral vector vaccines like ChAdOx1 nCoV-19.
• Clinical Expertise: Involvement in pivotal global trials across multiple phases, with emphasis on dose regimens, booster timing, and demographic variations in immune response.

Her publication portfolio demonstrates concentrated expertise in SARS-CoV-2 vaccine trials, spanning phase 1/2 to phase 3 randomized controlled studies across diverse populations and geographical settings. Key themes include prime-boost strategies, age-related efficacy, and real-world deployment challenges.

Susan Jackson operates within the McShane Group and Oxford Vaccine Group, critical units in the University of Oxford's response to tuberculosis and pandemic infectious diseases, leveraging institutional resources for translational vaccine research.